Utility of combining final PSA and PSA dynamics (change from month 6 to final PSA) for prostate cancer and high grade cancer diagnosis in the reduction by dutasteride of prostate cancer events (REDUCE) study
- G Andriole (Keynote speaker)
- S Freedland (Keynote speaker)
- D Tindall (Keynote speaker)
- Tammela, T. (Keynote speaker)
- C Teloken (Keynote speaker)
- M Somerville (Keynote speaker)
- T Wilson (Keynote speaker)
- R Rittmaster (Keynote speaker)
Activity: Talk or presentation › Invited lecture